2022
Tumor mutational burden (TMB) in immune checkpoint inhibitor (ICI)-naïve and -experienced patients with metastatic melanoma treated with lifileucel, a tumor-infiltrating lymphocyte (TIL) cell therapy.
Kluger H, Sarnaik A, Chesney J, Lewis K, Weber J, Gogas H, In G, Terheyden P, Lee S, Jagasia M, Masteller E, Qi R, Gontcharova V, Shi W, Fiaz R, Sulur G, Wu R, Chen G, Thomas S. Tumor mutational burden (TMB) in immune checkpoint inhibitor (ICI)-naïve and -experienced patients with metastatic melanoma treated with lifileucel, a tumor-infiltrating lymphocyte (TIL) cell therapy. Journal Of Clinical Oncology 2022, 40: 9524-9524. DOI: 10.1200/jco.2022.40.16_suppl.9524.Peer-Reviewed Original ResearchHigh tumor mutational burdenObjective response rateTumor mutational burdenCase-control studyAdvanced melanomaMetastatic melanomaTumor harvestResponse rateCell therapyT cell receptor repertoireLymphocyte cell therapyTumor microenvironment profilesImmune checkpoint inhibitorsPercentage of patientsTreatment of patientsHigh TMB groupMut/MbLogistic regression analysisICI exposureICI therapyRECIST v1.1Checkpoint inhibitorsStudy entryTMB groupBRAF status
2019
Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
Kim J, Kronbichler A, Eisenhut M, Hong S, van der Vliet H, Kang J, Shin J, Gamerith G. Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Cancers 2019, 11: 1798. PMID: 31731749, PMCID: PMC6895916, DOI: 10.3390/cancers11111798.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsProgression-free survivalTumor mutational burdenOverall survivalCheckpoint inhibitorsMutational burdenClinical trials of immune checkpoint inhibitorsPredictive value of tumor mutational burdenEfficacy of immune checkpoint inhibitorsTrials of immune checkpoint inhibitorsResponse to immune checkpoint inhibitorsHazard ratioImmune checkpoint inhibitor benefitTMB groupsImmune checkpoint inhibitor treatmentLow tumor mutational burdenLong-term survival outcomesLow TMB groupsBenefits of OSTMB groupRandomized Controlled TrialsSurvival outcomesRetrospective studyPatient groupClinical trials
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply